Duo Oncology
duooncology.com
Claim pageClaim
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$5.4M
5 rounds on record
Latest round
$4.3M
Venture round · Jan 2023 · 3 yr ago
Grants
$850k
2 grants · CORDIS
The money's age
Long since its last round
44 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 9
New executive Katherine Eichinger, Executive Officer · SEC Form D
Jun 2, 2025
Took on debt financing $1.6M · SEC Form D
Aug 15, 2024
Won a grant $400k · CORDIS
Sep 15, 2023
Won a grant $450k · CORDIS
Feb 8, 2023
Board appointment Robert Ashley, Director · SEC Form D
Jan 31, 2023
Raised a round Venture round $4.3M · SEC Form D
Feb 3, 2021
Raised a round Convertible Note $1.1M · SEC Form D
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Jun 2025 | $1.6M | — | SEC Form D |
| Grant | Aug 2024 | $400k | — | CORDIS |
| Grant | Sep 2023 | $450k | — | CORDIS |
| Venture round | Jan 2023 | $4.3M | — | SEC Form D |
| Convertible Note | Feb 2021 | $1.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Duo Oncology Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Jing-Zhou HouExecutive Officer, DirectorSEC Form D
Stephen ThorneExecutive OfficerSEC Form D
Sam RothsteinExecutive Officer, DirectorSEC Form D
Katherine EichingerExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Our Tumor Activated Permeability (TAP) Platform produces weakly-acidic derivatives of known oncology drugs that already work. It preserves…
Valink is developing a series of novel therapeutics that are more effective at attacking tumours, while sparing healthy tissue.
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
Valink is developing a series of novel therapeutics that are more effective at attacking tumours, while sparing healthy tissue.
Alveron Pharma is developing a unique coagulationplatform technology with the world.
People
Jing-Zhou Hou
Executive Officer, Director
Stephen Thorne
Executive Officer
Sam Rothstein
Executive Officer, Director
Katherine Eichinger
Executive Officer
Lusong Luo
Director
Song Li
Director
Stanley Marks
Director
Victoria Manax
Director
Joe Gatto
Director
Robert Ashley
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Pittsburgh
United States
HQ
Polymer Chemistry
122 Meyran Ave, Pittsburgh, PA 15213